Applying of different natural and synthetic excipients as in developing of drug forms as manufacturing various drug delivery systems was shown.

Effects such as excipients, type and general physico-chemical properties of drug form, some of technological manufacturing approaches of the drug forms on bioavailability were consider. Effects of the above-listed factors on the examples used in medical practice were demonstrated.

The role of cytochrome P450 isoforms CYP2C9 and in the metabolism of losartan described. Losartan pharmacokinetics data in humans and laboratory animals are presented. Examples of drug-drug interactions of substrate marker losartan of CYP2C9 of with different drugs are given. The results of studies of the effects of afobazole, an inducer (rifampicin) and inhibitors (fluconazole) in effective doses on the pharmacokinetics of losartan.

Rational pharmacotherapy is understood as intelligent drug combination and dosage adjustment for the purpose of drug adverse events development risk minimization and achievement of suitable therapeutical effect. One of the main factors affecting on drug potency is activity of biotransformation system. In this work, a review of promising "cocktail" method of biotransformation enzymes activity determination in vivo is given.

An experimental drug CBL0100 is developed as an antifungal agent for topical application. In order to assess the effect of composition of the formulation on transdermal absorption, a comparative absorption study of its pharmacokinetics and biodistribution after a single topical application on the guinea pigs' skin. Two different formulations of CBL0100 (prototypes of final dosage forms for topical applications) - cream emulsion and polyethylene glycol vehicles with a content of active substance 1, 0,2 and 0,02% mass. in each of these formulations were used in the study. CBL0100 concentration in blood plasma and homogenates of organs and tissues of animals was analyzed by HPLC - MS/MS. During the preliminary blood-to-plasma partitioning in vitro experiment it was determined that CBL0100 is found mostly in the cell fraction of the blood, which, based upon the pharmacokinetic curves shape affects elimination from plasma. It was revealed that after a single topical application active compound enters the systemic circulation and intensively distributed into the spleen, liver, kidneys and lungs of guinea pigs. At the same time, its content in the muscular tissue and the heart is negligible; CBL0100 moderately penetrates into the brain. In general, it was shown that the emulsion composition provides improved bioavailability of CBL0100 compared to the polyethylene glycol composition.

Efficiency and safety of Indigaplus in 25 patients with chronic prostatitis were studied. Drug administration makes positive impact upon the basic symptoms and signs of chronic prostatitis were proved. It enhances micturition, decreases pain syndrome, moderately decreases the volume of prostatic gland, enhances sexual-ejaculatory parameters and increases quality of life level.

In children oncology high doses of methotrexate (HD Mtx) use for treatment of osteosarcoma, acute lymphoblastic leukemia and many others tumors. Due to high intra- and interindividual Mtx pharmacokinetic variability it is essential perform monitoring its concentration in the saliva. The most dangerous phenomena in the case of HD Mtx are so-termed "delayed Mtx excretion", "prolonged Mtx excretion". Their development is multifactorial and unpredictable. Having big actual material we set task: analyze pharmacokinetics HD Mtx in case of osteosarcoma in children, determine its peculiarities, elucidate whether similar or not proceed disorders of Mtx excretion, perform their quantification.